These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6345992)

  • 1. Effect of nonesterified fatty acids on the stability of prostacyclin activity.
    Mikhailidis DP; Mikhailidis AM; Barradas MA; Dandona P
    Metabolism; 1983 Jul; 32(7):717-21. PubMed ID: 6345992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced prostacyclin survival after fasting-induced elevation of plasma free fatty acids.
    Goodnight SH; Inkeles SB; Kovach NL; Connor WE
    Thromb Haemost; 1985 Aug; 54(2):418-21. PubMed ID: 3909499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of prostacyclin in human plasma and whole blood: studies on the protective effect of albumin.
    Orchard MA; Robinson C
    Thromb Haemost; 1981 Oct; 46(3):645-7. PubMed ID: 7031983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of pH on the prostacyclin (PGI2) mediated inhibition of platelet function.
    Rao GH; Reddy KR; Hagert K; White JG
    Prostaglandins Med; 1980 Apr; 4(4):263-73. PubMed ID: 6994159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the stability of prostacyclin in human, rabbit and rat plasma.
    El Tahir KE; Williams KI; Betteridge DJ
    Prostaglandins Leukot Med; 1983 Feb; 10(2):109-14. PubMed ID: 6342001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of human plasma proteins on stabilisation of platelet anti-aggregatory activity of prostacyclin.
    Mikhailidis DP; Mikhailidis AM; Dandona P
    Ann Clin Biochem; 1982 Jul; 19 (Pt 4)():241-4. PubMed ID: 6181729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-aggregatory effect of prostacyclin (PGI2) in vivo.
    Bayer BL; Blass KE; Förster W
    Br J Pharmacol; 1979 May; 66(1):10-2. PubMed ID: 378308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostacyclin (PGI2) and the effect of phosphodiesterase inhibitors on platelet aggregation.
    Jørgensen KA; Dyerberg J; Stoffersen E
    Pharmacol Res Commun; 1979 Jul; 11(7):605-15. PubMed ID: 388470
    [No Abstract]   [Full Text] [Related]  

  • 9. Stability of prostaglandin I2 in human blood.
    Pifer DD; Cagen LM; Chesney CM
    Prostaglandins; 1981 Feb; 21(2):165-75. PubMed ID: 7012932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin-mediated neutralization of platelet antiaggregatory activity of prostacyclin (PGI2): studies on mechanism.
    Saba SR; Saba HI
    Am J Hematol; 1985 Oct; 20(2):97-105. PubMed ID: 3898823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 6-Keto-prostaglandin E1 inhibits the aggregation of human platelets.
    Wong PY; McGiff JC; Sun FF; Lee WH
    Eur J Pharmacol; 1979 Dec; 60(2-3):245-8. PubMed ID: 393526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of PGI2 and PGI2 analogues with increased stability on platelet cAMP content and aggregation.
    Blaskó G; Nemesánszky E; Szabó G; Stadler I; Pálos LA
    Thromb Res; 1980 Mar; 17(5):673-81. PubMed ID: 6247777
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of PGI2 on platelet aggregation and adenylate cyclase activity in human type IIa hypercholesterolemia.
    Colli S; Lombroso M; Maderna P; Tremoli E; Nicosia S
    Biochem Pharmacol; 1983 Jul; 32(13):1989-93. PubMed ID: 6347202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of albumin-bound unsaturated fatty acids on platelets.
    Refsum N; Lowery C; Nordøy A
    Haemostasis; 1981; 10(1):3-13. PubMed ID: 7203174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human platelet rich plasma and human serum protects from inactivation the antiaggregatory capacity of prostacyclin-like material (PGI2) produced by the rat stomach fundus.
    Borda ES; Lazzari MA; Gimeno MF; Gimeno AL
    Prostaglandins; 1980 Jun; 19(6):899-905. PubMed ID: 6992237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of the antiaggregatory activity of prostacyclin by propranolol in human platelets.
    Callahan KS; Johnson AR; Campbell WB
    Circulation; 1985 Jun; 71(6):1237-46. PubMed ID: 2986877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cardiovascular and platelet effects of epoprostenol (prostacyclin, PGI2) are unaffected by beta-adrenoceptor blockade in man.
    Hassan S; Pickles H; Fish A; Burke C; Warrington S; O'Grady J
    Br J Clin Pharmacol; 1982 Sep; 14(3):369-77. PubMed ID: 6127095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergism between prostacyclin (PGI2) and prazosin on human platelet aggregation.
    Moore PK
    Thromb Haemost; 1982 Feb; 47(1):76. PubMed ID: 7041326
    [No Abstract]   [Full Text] [Related]  

  • 19. Synergic effect of prostacyclin (PGI2) and alpha-blocking-agent on adrenalin-induced human platelet aggregation.
    Pogliani E; Fantasia R; Colombi M; Praga C
    Thromb Haemost; 1980 Oct; 44(2):106. PubMed ID: 6109380
    [No Abstract]   [Full Text] [Related]  

  • 20. Influence of albumin and non-esterified fatty acids on serum prostacyclin binding in pregnancy.
    O'Brien WF; Saba HI; Knuppel RA; Benoit R; Bruce A
    Prostaglandins; 1989 Jan; 37(1):61-7. PubMed ID: 2655012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.